Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415)

INTRODUCTION: Esophageal adenocarcinomas commonly express the Epidermal Growth Factor Receptor (EGFR). This trial assessed the six month overall survival probability in metastatic esophageal cancer patients treated with cetuximab as second line therapy. METHODS: This was a multicenter, open-label ph...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Gold, Philip J., Goldman, Bryan, Iqbal, Syma, Leichman, Lawrence P., Zhang, Wu, Lenz, Heinz-Josef, Blanke, Charles D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2928397/
https://ncbi.nlm.nih.gov/pubmed/20631636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181e77a92
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi